An algorithm to identify patients with rare genetic disorders and its real-world data application

3 4

5

PhD¹; David Corrigan, PhD¹; Lisong Shi, PhD¹; Seungwoo Lee, MS¹; Jonathan Tyler, PhD¹;
Shilong Li, PhD¹; Zichen Wang, PhD¹; Gustavo Stolovitzky, PhD¹; Lisa Edelmann, PhD¹; Rong
Chen, PhD¹; Eric E. Schadt, PhD^{1,4†}; Li Li, MD, MS^{1†}
¹GeneDx, Stamford, CT, USA.
²Department of Pediatrics, University of Wisconsin School of Medicine and Public Health,
Madison, WI, USA
³Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Bryn D. Webb, MD^{1,2*}; Lisa Y. Lau, PhD, MPH^{1*}; Despina Tsevdos, MD³; Ryan A. Shewcraft,

- ⁴Department of Genetics and Genomic Sciences, The Icahn Institute for Genomics and
- 15 Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- 16
- 17 *Contributed equally as co-first authors
- ⁺ Contributed equally as co-senior authors; corresponding authors
- 19 20 **C**

20 Corresponding authors' details

- 21 Name: Li Li
- 22 Address: 333 Ludlow St, Stamford, Connecticut 06902, USA
- 23 Telephone: 475-533-3720
- 24 Email: <u>li.li@sema4.com</u>
- 25
- 26
- 27 Short Title: Identifying patients with rare genetic disorders
- 28 29
- 30 Conflict of Interest Disclosures: The authors have no conflicts of interest relevant to this article
 31 to disclose.
- 32
- 33
- Funding/Support: None. This project was performed in collaboration with GeneDx. GeneDx is a company that integrates genetic testing and data analytics to improve diagnosis, treatment, and
- 36 prevention of disease. The Icahn School of Medicine at Mount Sinai holds equity in this for-
- 37 profit company.
- 38

39 Abbreviations

- 40 CSER Clinical Sequencing Exploratory Research
- 41 CS carrier screening
- 42 CS-L carrier screening, large panel
- 43 CS-M carrier screening, medium panel
- 44 CS-S carrier screening, small panel
- 45 CT computed tomography
- 46 CTICU cardiothoracic intensive care unit
- 47 eMERGE Electronic Medical Records & Genomics EHR
- 48 EMR electronic medical record
- 49 ER emergency room
- 50 ICD International Classification of Diseases
- 51 MRI magnetic resonance imaging
- 52 MSHS Mount Sinai Health System
- 53 NICU neonatal intensive care unit
- 54 NPV negative predictive value
- 55 PPV positive predictive value
- 56

5758 Article Summary:

- 59 Algorithm using EMR data to identify children who have been diagnosed with a genetic disorder
- 60 or present with illness with increased risk of genetic disorders.
- 61

62

63 What's known on this subject:

- 64 With over 7000 Mendelian disorders, identifying children with a specific rare genetic disorder
- 65 diagnosis through structured EMR data is challenging given incompleteness of records,
- 66 inaccurate medical diagnosis coding, as well as heterogeneity in clinical symptoms and
- 67 procedures for specific disorders.
- 68

69

70 What this study adds:

- 71 We developed a digital phenotyping algorithm using electronic medical records (EMR) data to
- 72 identify children aged 0-3 who have been diagnosed with genetic disorders or present with
- 73 illness with an increased risk for genetic disorders from a mother-child cohort.
- 74

75 Author Contributions Statement Page

76

Dr. Bryn Webb interpreted the data and results, carried out chart review, drafted the manuscript,and critically reviewed and revised the manuscript.

- 79
- 80 Dr. Lisa Lau coordinated data collection, analyzed, and interpreted the data; drafted the
- 81 manuscript, and critically reviewed and revised the manuscript.82
- 83 Dr. Despina Tsevdos carried out chart review, drafted, reviewed, and revised the manuscript.
- B5 Dr. Ryan Shewcraft analyzed the data, drafted the manuscript, reviewed, and revised the
 manuscript.
- 87

- 88 Seungwoo Lee, Drs. David Corrigan, Lisong Shi, Jonathan Tyler, Shilong Li, Zichen Wang, Lisa
- 89 Edelmann, and Gustavo Stolovitzky participated in acquisition of data, interpreted the data,
- 90 participated in drafting the manscript, and revised the manuscript.
- 91
- Dr. Rong Chen designed the study, collected, analyzed, and interpreted the data; criticallyreviewed and revised the manuscript.
- 93 94
- 95 Drs. Li Li and Eric Schadt conceptualized, designed, and supervised the study; collected the data,
- 96 interpreted the data and results, drafted the manuscript, critically reviewed and revised the97 manuscript.
- 98
- All authors approved the final manuscript as submitted and agree to be accountable for all
- 100 aspects of the work.

101 Abstract

102 *Objectives*

103 Develop a digital phenotyping algorithm (PheIndex) using electronic medical records (EMR)

104 data to identify children aged 0-3 who have been diagnosed with genetic disorders or present

105 with illness with an increased risk for genetic disorders from a mother-child cohort.

- 106
- 107 Methods
- 108 We established 13 criteria for the algorithm where two metrics a quantified score and a
- 109 classification were derived. The criteria and the classification were validated by chart review
- 110 from a pediatrician and clinical geneticist. To demonstrate the utility of our algorithm in real-
- 111 world evidence applications, we examined the association between size of carrier screening
- 112 panel (small/≤4 genes [CS-S] vs large/≥100genes [CS-L]) undertaken by mothers prior to
- 113 delivery, and children classified as presenting with illness with an increased risk for genetic
- 114 disorders by our algorithm.
- 115
- 116 Results
- 117 The PheIndex algorithm identified 1,088 such children out of 93,154 live births and achieved
- 118 90% sensitivity, 97% specificity, and 94% accuracy by chart review. We found that children

119 whose mothers received CS-L were less likely to be classified as presenting with illness with an

120 increased risk for genetic disorders and a decreased need to have multiple specialist visits and

- 121 multiple ER visits, compared to children whose mothers received CS-S.
- 122
- 123 Conclusions
- 124 The PheIndex algorithm can help identify when a rare genetic disorder may be present, and has
- 125 the potential to improve healthcare delivery by alerting providers to consider ordering a
- 126 diagnostic genetic test and/or referring a patient to a medical geneticist or other specialists.
- 127

128 Introduction

129 The widespread adoption of electronic medical record (EMR) systems has the potential to enable large-scale population-based studies characterizing patients with rare disorders.¹ While 130 131 identifying genomic information from EMR systems would assist in identifying such patient 132 populations, with groups from Clinical Sequencing Exploratory Research (CSER) and Electronic 133 Medical Records & Genomics © (eMERGE) representing such efforts, they have noted that 134 genetic information is most commonly stored in unstructured formats such as PDF files or in paragraphs of free text, making genetic testing results difficult to locate.^{2,3} Additionally, CSER 135 136 and eMERGE have not pursued a global approach to identifying patient populations with 137 confirmed genetic disorders, or patients yet to be diagnosed with a genetic condition but rather 138 whose medical records indicate that diagnostic genetic testing is warranted. Indeed, digital 139 phenotyping studies using EMR data have largely focused on identifying populations with 140 specific individual diseases, such as extracting patients with pediatric epilepsy, childhood obesity, or Noonan syndrome.⁴⁻⁷ 141 142 When using EMR data to identify patient populations affected with rare genetic disorders, 143 focusing on a specific rare genetic disorder diagnosis for any given patient is error-prone for 144 many reasons. First, of 6519 rare disorders assessed, only 11% have International Classification 145 of Disease 9 (ICD-9) codes and 21% have ICD-10 codes; some ICD codes are nonspecific, often

146 with multiple phenotypes corresponding to a single ICD code.⁸ Furthermore, physicians and 147 clinicians sometimes log certain ICD codes as they rule in or out a given condition, or when a 148 condition is part of a differential diagnosis, yet still unconfirmed. Diagnosis codes may also be 149 inaccurate or incomplete.⁹

150 Accordingly, algorithms that assess the risk of genetic disorders have the potential to 151 improve healthcare delivery by assisting physicians and clinicians with clinical decision-making, 152 including guiding when to order a diagnostic genetic test and/or refer a patient to a medical 153 geneticist or other specialists may be indicated. Further, such algorithms could also be leveraged 154 to identify rare genetic disorders patient populations to carry out cross-sectional and longitudinal 155 epidemiological studies, assess healthcare utilization, and flag patients who may be considered 156 for participation in specialized undiagnosed disease programs and precision medicine initiatives as underdiagnosis of rare genetic disorders is not uncommon.¹⁰ 157

158 As a collaborative, multidisciplinary team, we developed a digital phenotyping algorithm 159 that used structured EMR data and assessed 13 criteria to identify patients from birth to 3 years 160 of age who have been diagnosed with a rare genetic disorder or who are at high risk for such a 161 diagnosis. We tested our algorithm using a real-world dataset comprised of 93,154 live births 162 with children linked to mothers' medical records in a large academic health system. We 163 validated the algorithm through blinded chart review by a pediatrician and a clinical geneticist. 164 To demonstrate the real-world evidence application of our algorithm, we examined the 165 health outcomes of children whose mothers received carrier screening; specifically, whether 166 there was an association between children who were classified as presenting with illness with an 167 increased risk for genetic disorders by our algorithm, and the size of the carrier screening panel 168 received by the mothers of these children. To the best of our knowledge, we are the first to 169 generate a digital phenotyping algorithm beyond using ICD codes to identify children presenting 170 with illness with an increased risk for genetic disorders and employed this algorithm to assess 171 healthcare outcomes in a large, diverse, pediatric population.

172

173 Methods

174 Construction of mother-child cohort

175 We obtained de-identified EMR data through June 30, 2020 from the Mount Sinai Health 176 System (MSHS). In total, we identified 93,154 mother-child pairs delivered at MSHS hospitals, covering 68,893 mothers and 93,154 children.¹¹⁻¹³ The newborns in this cohort were born from 177 178 2007 to 2019, ensuring that all newborns had at minimum one year of follow-up (see also 179 Supplemental Materials). This study was approved by the Mount Sinai institutional review board 180 (IRB): IRB-20-01771. 181 182 Digital phenotyping algorithm for rare genetic disorders 183 The *PheIndex* (Phenotype Index) digital phenotyping algorithm was developed based on 184 13 criteria that may be present in children with a rare genetic disorder. These criteria are 185 primarily based on healthcare utilization patterns such as hospital encounters, procedures, 186 specialist visits, and laboratory test orders. Orders that were subsequently cancelled were not 187 considered. Additional criteria that were included were diagnostic codes of developmental delay 188 and metabolic disease, and death. Description of the criteria with the associated scores is listed in 189 Table 1. 190 *PheIndex* combines these criteria in two different ways: (1) "*PheIndex Score*", a

Themaex combines these cifienta in two different ways. (1) *Themaex score*, a

191 quantified score indicating the severity of illness with a possible range between 0 and 24

192 generated by the sum of the score(s) associated with the criteria met by a child; and (2)

193 *"PheIndex Classification"*, a binary classification of those who present with illness with an

194 increased risk for genetic disorders (*PheIndex Classification* positive) if the following conditions

195 are met: (a) ≥ 2 major criteria, (b) ≥ 1 major criteria and ≥ 1 minor criteria, (c) ≥ 5 minor criteria, or

(d) deceased patient; or those who do not present illness with increased risk for genetic disorders
(*PheIndex Classification* negative).

198

199 Chart review verification of the PheIndex digital phenotyping

200 For the blinded chart review, we selected 200 charts consisting of children who were 201 *PheIndex Classification* positive (N=100) and *PheIndex Classification* negative (N=100). We 202 ensured that the 100 children who were negative covered quantified scores from 0 to 6 203 (inclusive), and from 3 to 21 for 100 children who were positive, based on the distribution of the 204 *PheIndex Score.* Available records for this review were from encounters dated 01/01/2005 to 205 06/30/2020. All criteria determinations were based on available medical records up until three 206 years of age. The review by the pediatrician had two steps: 1) validate the accuracy of the values 207 assigned to each of the 13 criteria for each patient; and 2) summarize diagnostic information 208 from the patient charts. The pediatrician had access to additional delivery notes, progress notes, 209 admission/discharge summaries, and imaging notes. Information on diagnoses available in the 210 notes documented by the pediatrician was then used by a clinical geneticist to decide whether the 211 child presented with illness with an increased risk for genetic disorders. The possible categories 212 of determination were: 1) "Definitively/possibly has genetic disorder diagnosis", 2) "Does not 213 have a genetic disorder", 3) "Unknown, insufficient information to make determination on 214 whether a genetic disorder was related with illness."

215

216 Statistical analysis

217 Full details are described in Supplemental Materials.

219 **Results**

220 Distribution of the 13 criteria in PheIndex

221 Our cohort included 93,154 newborns linked to 68,893 mothers who delivered in the MSHS

- from 2007 to 2019, with clinical features collected to 2020 (Table 2). We first assessed the
- 223 frequency of each of the 13 PheIndex digital phenotyping criteria in our cohort and summarized
- the number of children aged 0 to 3 years old that satisfied each of the 13 criteria (Table 3). The
- most common criteria were multiple ER visits (3,919; 4.22%), followed by developmental delay
- 226 (3,159; 3.39%), and multiple visits to specialists (3,091; 3.32%). The least common criteria were
- 227 metabolic disease diagnosis codes (82; 0.09%) and feeding support (132; 0.14%). Figure 1A and
- 1B demonstrate the expected temporal relationship for achieving each criterion.

229 We generated a heatmap to show the number and percentage of patients who fell into 230 different major and minor criteria combinations (Figure S1). The distribution for the total 231 number of criteria for each child is given in Figure 1C. A large majority of patients (88.51%) did 232 not meet any of the 13 criteria, and 98.55% met ≤ 2 criteria. We showed the distribution of 233 *PheIndex Classification* – children who presented with illness with an increased risk for genetic 234 disorders or not – stratified by the *PheIndex Score* (Figure 1D), as the *PheIndex Classification* 235 depends on the specific combination of major and minor criteria for each patient. The majority of 236 patients had a *PheIndex Score* ≤ 2 (97.23%), indicating that most children in our study 237 population were not likely to have a rare genetic disorder. With our 13 criteria, the *PheIndex* 238 *Classification* identified 1,088 children who were presenting with illness with an increased risk 239 for genetic disorders out of 93,154 children (1.2%).

Hospital utilization patterns are known to vary between pre-term and full-term infants,
e.g. pre-term infants often have more prolonged NICU stays. To assess this, we computed the

similarity between all pairs of *PheIndex* criteria using the Jaccard index for each group (Figure
1E and 1F, Supplemental Materials). In the full-term cohort, *heart surgeries* and *prolonged NICU stay* had the highest Jaccard similarity of 0.44, in line with what we would expect to
observe clinically. In the preterm cohort, prolonged NICU stay was not chosen to be a criterion
because the majority of preterm infants have an extended NICU stay regardless of whether they
have a rare genetic disorder or not.

248

249 Validation of PheIndex: 13 Criteria and Overall Classification

250 First, we evaluated the accuracy of the values that were extracted from the EMR and 251 assigned to the 13 different criteria for each patient, by comparing *PheIndex*'s identification of 252 each of the 13 criteria against a pediatrician's evaluation directly from the clinical notes for each 253 patient, for a sample of 200 children (Table 4). The 200 children were sampled from those 254 classified as presenting with illness with an increased risk for genetic disorders positive for a rare 255 genetic condition (N=100) and those classified as negative (N=100). From this comparison, our 256 digital phenotyping algorithm achieved an average accuracy of 94% across the 13 criteria. 257 Accuracies were $\geq 90\%$ for all criteria except for "*prolonged NICU stays*", which yielded an 258 accuracy of 81%.

Next, we compared the *PheIndex Classification* against the classifications made by a pediatrician/medical geneticist (Table 5). Among the 200 children reviewed, 12 patients did not have sufficient clinical information for the medical geneticist to assess whether a genetic disorder may be present. Ten of these 12 patients were born extremely prematurely (born before 28 gestational weeks), which led to uncertainties as to whether the criteria that were met was because of prematurity or because of an underlying genetic disorder (as determined by the medical geneticist). Therefore, these 12 patients were excluded from this performance evaluation.

266	Among the 188 patients remaining (88 classified as positive by PheIndex and 100 classified as
267	negative), 85 patients were deemed to be true positives (definitively or possibly has a rare
268	genetic disorder by chart review, 90% sensitivity/recall) and 91 patients were deemed to be true
269	negatives (does not have a genetic disorder, 97% specificity). Three patients who were classified
270	as positive by <i>PheIndex</i> were not thought to have a genetic disorder (false positive), and 9
271	patients were thought to definitively or possibly have genetic disorders but were classified as
272	having no genetic disorders by <i>PheIndex</i> (false negative), yielding a positive predictive value
273	(PPV) of 97%, negative predictive value (NPV) of 91%, and 94% accuracy. If we considered the
274	prevalence of rare genetic disorders to be 3-3.6% of all livebirths, ¹⁴ the adjusted PPV ranges
275	from 48.1% to 48.3%. ¹⁵
276 277	PheIndex Scores by Carrier Screening Gene Panel Size
278	We examined the association between the PheIndex Score, an indicator of disease
279	severity, and the three panel sizes (CS-S, CS-M, and CS-L). We first identified that 3 PheIndex
280	criteria (multiple inpatient hospital stays, genetic testing, and developmental delay) were
281	enriched for infants whose mothers had performed only CS-S testing compared with CS-M and
282	CS-L (Table 6). For patients with at least 1 year of follow-up, we observed that the overall
283	PheIndex Scores were higher in CS-S (mean=0.70) compared to CS-M (mean=0.38, p<0.001)
284	and CS-L (mean=0.57, p<0.001) (Figure 3A); and CS-S (mean=0.85) compared to CS-M
285	(mean=0.47, p<0.001, Student's T-test) and CS-L (mean=0.70, p<0.001) for patients with at least
286	2 years of follow-up (Figure 3D).
287	

288 Comparison of time to onset for each criterion for CS-S and CS-L

289	To investigate the contributions of clinical factors to the <i>PheIndex</i> criteria and scores
290	over time, we performed a sub-analysis between the CS-S and CS-L groups. We computed
291	Kaplan-Meier survival curves for each of the 13 criteria for the CS-S and CS-L groups (Figure 4,
292	Supplemental Figure 2) to examine the association of outcomes with time. We found that
293	children in the CS-L cohort were less likely to see multiple specialists (p<0.001, Figure 4A),
294	have multiple visits to the ER (p<0.001, Figure 4B), and less likely to undergo heart surgeries
295	(p=0.06) or die early in childhood (p=0.058), compared to children in the CS-S cohort.
296	
297	Regression Analysis
298	In the Cox proportional hazards model, we found that for children whose mothers were
299	administered a CS-L panel, a 36% (p=0.005) reduction of being classified as presenting with
300	illness with an increased risk for genetic disorders was estimated, compared to the children
301	whose mothers ordered were administered a CS-S panel test (Supplemental Figure 4).
302	
303	Discussion
304	Identifying pediatric patients across an entire population with or who possibly has a rare
305	genetic disorder is critical for improving patient outcomes. We and others have attempted to
306	identify patients with specific genetic disorders using EMR data, but have found that such a
307	process is not straightforward, largely due to coding differences, unconfirmed diagnoses,
308	variation in disease names and terminology, and inaccurate information represented in medical
309	records. ^{16,17} For most rare genetic disorders, it is difficult to identify patients with specific
310	genetic disorders, given ICD codes are often nonspecific. ^{1,18,19} Additionally, seeking to analyze
311	individual diseases, even in EMR databases with millions of patients, would result in

312 underpowered studies given the low frequency of individual rare genetic disorders. However, by 313 using a global metric as opposed to ones derived from specific individual diseases, we were able 314 to identify a large cohort that provided for sufficient statistical power to assess the association of 315 differently sized CS panels with risk of genetic disorders.

316 In this study, we developed a novel, rule-based digital phenotyping algorithm (*PheIndex*) 317 that utilizes 13 criteria to derive a *PheIndex Score* for children from birth to 3 years of age, in 318 order to classify whether a child is presenting with an illness that may be a rare genetic disorder. 319 Importantly, our score is an evaluation of overall health rather than the presence of specific 320 features of individual diseases. To our knowledge, such an approach has not been developed 321 previously. The criteria for the *PheIndex Score* include items that could be extracted from the 322 EMR with a high degree of precision and accuracy. Our PheIndex Score may be utilized for 323 various purposes, including its use as a clinical guide to shorten the diagnostic odyssey of hard-324 to-diagnose patients, timely administration of therapeutics by facilitating more rapid diagnosis, 325 and/or assessing clinical benefit of genetic testing, all of which help enable the practice of 326 precision medicine in a way that may be more accessible to all. Chart review from clinical 327 genetics experts, confirmed that our *PheIndex* algorithm has the following performance 328 characteristics when the numbers of cases and controls are equal: precision of 97%, recall of 329 90%, and accuracy of 94%.

To demonstrate the ability of our algorithm to identify an enriched set of patients at risk of harboring a rare genetic condition, we leveraged carrier screening results in mothers who delivered a baby in a large health system. We examined the association between a mother's carrier screening panel size and *PheIndex Score*. We found that CS-L was not only associated with a lower overall *PheIndex Score*, but was also significantly associated with a decreased need

335 for a child having multiple specialist visits and multiple ER visits. In our sub-analysis using a 336 cohort of mother-child pairs whose mother received CS-L or CS-S and with whom the child 337 received at least two years of follow-up, we noted that those in the CS-L group reached the 338 criteria of *multiple specialists* and *genetic diagnostic tests* earlier than those in the CS-S group. 339 This result is notable as it supports that administration of a CS-L panel test may enable earlier 340 diagnosis of genetic disorders in children. Alternatively, testing using a CS-L panel may increase 341 awareness of parental carrier status, thus enabling prenatal diagnostic testing for a larger number 342 of conditions. This increased awareness may also lead to early referral of children manifesting 343 severe illness for rare genetic diagnostic testing and subsequent referrals to the appropriate 344 specialists and potentially earlier treatment. Parental carrier status may also lead to earlier 345 postnatal diagnostic genetic testing and thus confirmation of a particular genetic disorder.

346

347 *Limitations*

348 While our study population is likely representative of other large, diverse metropolitan 349 areas, it may be less representative of smaller-sized cities and rural areas. Also, we provided an 350 adjusted PPV of 48% based on an estimated prevalence of rare genetic disorders in the general 351 population. However, precise estimates of rare genetic disorder prevalence are unavailable, and 352 may also not reflect the PPV for the target population of our algorithm (i.e. children aged 0-3) due to differences in age of onset.¹⁴ Another potential limitation of our study is that we used only 353 354 de-identified data available in structured EMR databases, and thus did not include all the 355 information that would be available to physicians, such as clinical notes. However, despite not 356 having access to all available clinical notes, our digital phenotype agreed with physician chart 357 review 94% of the time (under conditions in which the number of cases and controls were

sampled to be the same), proving that our algorithm successfully identifies children possibly with 358 359 rare genetic disorders. In the few occasions where there were discrepancies, this was typically 360 due to incomplete documentation of orders, such as respiratory support and feeding support in 361 *PheIndex* negative children that was uncovered in the notes during chart review. Thus, we 362 believe that our digital phenotype will be more accurate using the *PheIndex* criteria extracted 363 from notes in addition to structured EMR data. With respect to demonstrating the application of 364 PheIndex across groups receiving comprehensive carrier screening and those receiving reduced 365 or no carrier screening, the MSHS is unique in that beginning in 2016, CS-L was offered to all 366 women considering pregnancy or already pregnant regardless of the mother's ability to pay or 367 health insurance coverage. Notably, our cohort is comprised of linked mother-child pairs and 368 thus does not directly assess the rate of mothers who chose not to continue pregnancies with an 369 affected fetus; however, the improvement in health of children whose mothers received CS-L 370 may be due to couples choosing to proceed with various reproductive health options such as in 371 *vitro* fertilization (IVF), in order to reduce the chances of having a child affected with one of as 372 many as 283 genetic conditions assessed in the CS-L panel described in our study. Additionally, 373 mothers who chose to receive CS-L may be more likely to complete additional genetic testing 374 via chorionic villus sampling or amniocentesis in the setting of advanced maternal age or family 375 history of genetic disorders. Moreover, while we controlled for differential follow-up time and 376 likely confounders, there may still be unmeasured confounding in the Cox regression model.

377

378 Conclusions

In summary, we utilized a comprehensive EMR to develop a novel digital phenotypingalgorithm for identification of a pediatric population with a definitive or possible genetic

381 disorder. Our method utilizes a global approach as opposed to identifying patients in the EMR 382 with each specific genetic disorder, which is fraught for misdiagnoses and error. In addition, our 383 study is the first with adequate sample size and follow up to evaluate the health of children from 384 birth to 3 years of age. Using a mother-child cohort that links children to mothers' genetic carrier 385 screening status, we have identified that PheIndex Scores are lower at one or two years of 386 follow-up in children whose mothers received CS-L relative to CS-S. We believe that our 387 *PheIndex* algorithm will address an unmet need to identify children with rare genetic disorders 388 and potentially help overcome well-known obstacles such as underdiagnosis and delayed diagnosis.²⁰ 389

390

391 ACKNOWLEDGEMENTS

392 We would like to thank Drs. Mitchell K. Higashi and Paul Kruszka for reviewing the manuscript

393 and Mount Sinai Data Warehouse for EMR data. We also thank the GeneDx IT team for

infrastructural and computational support.

REFERENCES

1. Garcelon N, Burgun A, Salomon R, Neuraz A. Electronic health records for the diagnosis of rare diseases. *Kidney Int*. 2020;97(4):676-686. doi:10.1016/j.kint.2019.11.037

2. Shirts BH, Salama JS, Aronson SJ, et al. CSER and eMERGE: current and potential state of the display of genetic information in the electronic health record. J Am Med Inform Assoc. Nov 2015;22(6):1231-42. doi:10.1093/jamia/ocv065

3. Williams MS, Taylor CO, Walton NA, et al. Genomic Information for Clinicians in the Electronic Health Record: Lessons Learned From the Clinical Genome Resource Project and the Electronic Medical Records and Genomics Network. Front Genet. 2019;10:1059. doi:10.3389/fgene.2019.01059

4. Yang Z, Shikany A, Ni Y, Zhang G, Weaver KN, Chen J. Using deep learning and electronic health records to detect Noonan syndrome in pediatric patients. Genet Med. Nov 2022;24(11):2329-2337. doi:10.1016/j.gim.2022.08.002

5. Cohen KB, Glass B, Greiner HM, et al. Methodological Issues in Predicting Pediatric Epilepsy Surgery Candidates Through Natural Language Processing and Machine Learning. Biomed Inform Insights. 2016;8:11-8. doi:10.4137/BII.S38308

6. Lingren T, Thaker V, Brady C, et al. Developing an Algorithm to Detect Early Childhood Obesity in Two Tertiary Pediatric Medical Centers. Appl Clin Inform. Jul 20 2016;7(3):693-706. doi:10.4338/ACI-2016-01-RA-0015

7. Wang Y, Wang L, Rastegar-Mojarad M, et al. Clinical information extraction applications: A literature review. J Biomed Inform. Jan 2018;77:34-49. doi:10.1016/j.jbi.2017.11.011

8. Fung KW, Richesson R, Bodenreider O. Coverage of rare disease names in standard terminologies and implications for patients, providers, and research. AMIA Annu Symp Proc. 2014;2014:564-72.

9. Horsky J, Drucker EA, Ramelson HZ. Accuracy and Completeness of Clinical Coding Using ICD-10 for Ambulatory Visits. AMIA Annu Symp Proc. 2017;2017:912-920.

10. Petrikin JE, Willig LK, Smith LD, Kingsmore SF. Rapid whole genome sequencing and precision neonatology. Semin Perinatol. Dec 2015;39(8):623-31. doi:10.1053/j.semperi.2015.09.009

11. Zheutlin AB, Vieira L, Shewcraft RA, et al. A comprehensive digital phenotype for postpartum hemorrhage. J Am Med Inform Assoc. Jan 12 2022;29(2):321-328. doi:10.1093/jamia/ocab181

12. Zheutlin AB, Vieira L, Shewcraft RA, et al. Improving postpartum hemorrhage risk prediction using longitudinal electronic medical records. J Am Med Inform Assoc. Jan 12 2022;29(2):296-305. doi:10.1093/jamia/ocab161

13. Li S, Wang Z, Vieira LA, et al. Improving preeclampsia risk prediction by modeling pregnancy trajectories from routinely collected electronic medical record data. NPJ Digit Med. Jun 6 2022;5(1):68. doi:10.1038/s41746-022-00612-x

14. Ferreira CR. The burden of rare diseases. Am J Med Genet A. 2019;179(6):885-892. doi:10.1002/ajmg.a.61124

15. Tenny S, Hoffman MR. Prevalence. [Updated 2022 May 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430867/ [Accessed 2022 Nov 12]

16. Miller KE, Hoyt R, Rust S, Doerschuk R, Huang Y, Lin SM. The Financial Impact of Genetic Diseases in a Pediatric Accountable Care Organization. *Front Public Health*. 2020;8:58. doi:10.3389/fpubh.2020.00058

17. Tisdale A, Cutillo CM, Nathan R, et al. The IDeaS initiative: pilot study to assess the impact of rare diseases on patients and healthcare systems. *Orphanet J Rare Dis.* 2021;16(1):429. doi:10.1186/s13023-021-02061-3

18. Aymé S, Bellet B, Rath A. Rare diseases in ICD11: making rare diseases visible in health information systems through appropriate coding. *Orphanet J Rare Dis.* 2015;10:35. doi:10.1186/s13023-015-0251-8

19. Navarrete-Opazo AA, Singh M, Tisdale A, Cutillo CM, Garrison SR. Can you hear us now? The impact of health-care utilization by rare disease patients in the United States. *Genet Med*. 2021;23(11):2194-2201. doi:10.1038/s41436-021-01241-7

20. Zanello G, Chan CH, Pearce DA; IRDiRC Working Group. Recommendations from the IRDiRC Working Group on methodologies to assess the impact of diagnoses and therapies on rare disease patients. *Orphanet J Rare Dis.* 2022;17(1):181. doi:10.1186/s13023-022-02337-2

Figure Captions

Figure 1. Distribution of *PheIndex* critera of children in the cohort.

(A,B) Cumulative distribution of time when patients first meet each of the 13 *PheIndex* criteria. Only patients that met each criterion within the three-year limit were included in each cumulative distribution. (A) is sorted by the percentage of patients meeting the criteria at 200 days (least number of patients at the top).

(C) Bar graph showing the showing the number and percentage of patients with passing different numbers of *PheIndex* criteria.

(D) Distribution of *PheIndex* scores for children within the mother-child cohort.

(E,F) Clustered heatmap showing the Jaccard index between possible pairs of *PheIndex* criteria in the pre-term (E) and full-term (F) cohorts. The number and percentage of patients for each criterion are labeled.

Figure 2. Summary statistics of the genetic carrier screening status for newborns in the mother-child cohort.

(A) Top: Numbers of newborns whose mothers were tested with different genetic carrier screens arranged by years of birth (YOB).

Bottom: Percentages of newborns whose mothers were tested with different genetic carrier screens arranged by YOB.

(B) Histogram showing the distribution of genetic carrier tests dates (by month) relative to delivery (inset, weekly).

Figure 3. *PheIndex* Scores across the carrier screening (CS) testing cohort stratified by length of follow-up.

(A) Average *PheIndex* score from the digital phenotype for all children with ≥ 1 year of followup in each CS testing cohort. Error bars show 95% confidence interval. *** denotes p<0.001.

(B) Violin plot of *PheIndex* scores using the same categories as (A), but only including children labelled as "positive" from digital phenotype.

(C) Percentage of children labelled as "positive" for each CS testing cohort. Error bars show 95% confidence interval. (D-F) Same as (A-C) but only including children with at least two years of follow-up.

Figure 4. Kaplan-Meier curves stratified by carrier screening panel size, Carrier screening, small panel / CS-S (blue) vs Carrier screening, large panel / CS-L (orange).

(A) Shows that children whose mothers received CS-S met the multiple specialist criterion in a greater proportion than those whose mothers received CS-L at three years of follow-up.

(B) Shows that children whose mothers received CS-S met the multiple ER visits criterion in a greater proportion than those whose mothers received CS-L at three years of follow-up. Shaded areas denote 95% confidence interval.

Figure 1



Figure 2





CS-S: small panel; CS-M: medium panel; CS-L: large panel

panel

Figure 4





Table 1: Description and scoring for the 13 PheIndex criteria

Description	Scoring
Prolonged stay in the neonatal intensive care unit (NICU) for term babies. Full-term newborns who were admitted to the NICU and stayed for >4 days	Major; score = 3
Prolonged or multiple hospitalizations after discharged from birth. Hospitalization is defined	
as inpatient stays with a duration \geq 48 hours. We included hospital stays where the calculated gestational age is older than 35 weeks and exclude the first newborn encounter if earlier than 35-week gestation. To meet this criterion, the patient must have either at least one prolonged hospitalization (\geq 14 days) or at least two hospitalizations (\geq 48 hours duration) for full-term or \geq 3 hospitalizations (\geq 48 hours) for pre-term babies.	Major; score = 3
Visits or consults with multiple specialists other than general pediatricians. Twenty types of specialists were considered: Medical Genetics, Neurosurgery, Pediatric Allergy and Immunology, Pediatric Cardiology, Pediatric Dermatology, Pediatric Endocrinology, Pediatric GI/Pediatric Liver, Pediatric Hematology/Oncology, Pediatric Nephrology, Pediatric Neurology, Pediatric Ophthalmology, Pediatric Orthopedics, Pediatric Otolaryngology, Pediatric Pulmonology, Pediatric Rheumatology, Pediatric Surgery, Pediatric Urology, Transplant, Plastic Surgery. We counted the types of specialists each patient visited or consulted with and not the number of individual specialist visits. Preterm babies with ≥ 4 types of specialists or full-term babies with ≥ 3 types of specialists meet this criterion. We excluded Pediatric Infectious Disease speciality visits as infections in general are primarily due to environmental and non-genetic etiologies, and our aim was to identify a patient population enriched for children with genetic disorders.	Minor; score = 1
<i>Multiple emergency room (ER) visits.</i> Full-term babies with \geq 5 ER visits or preterm babies with \geq 7 ER visits meet this criterion.	Minor; score = 1
<i>Feeding support (Gastrostomy tube).</i> Patients who required feeding support were identified using ICD codes (Supplemental Table 2A) and procedures with description of "nasogastric", "gastrostomy" and "feed", or "gastrostomy" and "tube" in the procedure name.	Minor; score = 2
Respiratory support (tracheostomy and mechanical ventilation outside of surgery). We used tracheostomy and ventilation (including CPAP) identified by procedure codes and diagnosis codes. If a surgical procedure was performed, the ventilatory support was required to be performed either 1 day before or 5 days after surgeries to be able to meet this criterion.	Minor; score = 2
<i>Imaging.</i> We included patients that received computed tomography (CT) or magnetic resonance imaging (MRI) with completed encounter order status or preliminary/final results available from radiological exams.	Minor; score = 1
<i>Genetic diagnostic tests.</i> We included patients who received genetic diagnostic tests such as gene sequencing or array comparative genomic hybridization regardless of test results. The records of genetic diagnostic tests were retrieved from procedure codes and labs.	Minor; score = 1
<i>Metabolic diagnostic tests.</i> We included patients who received metabolic tests such as plasma amino acids panel or urine organic acids panel, regardless of test results. The records of metabolic diagnostic tests were retrieved from procedure codes and labs.	Minor; score = 1
<i>In-hospital death.</i> Death information was retrieved from discharge location/disposition (expired, to funeral home/morgue or organ harvest) from encounter records.	Major; score = 3
Developmental delay. Patients with developmental delay were identified by either a specialist visit with a developmental pediatrician or at least two occurrences of related ICD codes (Supplemental Table 2B)	Minor; score = 1
Diagnosis codes corresponding to metabolic diseases with ≥ 2 encounters, (major, score=3). We included patients with ICD codes for metabolic diseases (Supplemental Table 2C).	Major; score $= 3$

Description	Scoring
<i>Heart surgeries, (major, score=3).</i> Newborns that received heart surgeries were identified by encounters related to cardiothoracic surgeries or cardiothoracic intensive care unit (CTICU).	Major; score = 3

			CS-S	CS-M	CS-L	All	p-value	Test
		#	9786	7130	14264	93154		
	R	Delivery age, median [Q1,Q3] ace, n (%)	32.9 [29.4,36.2]	34.3 [31.5,37.2]	33.7 [30.6,36.7]	32.5 [28.2,36.1]	< 0.001	Kruskal- Wallis
		African-American/Black	1475 (15.1)	142 (2.0)	1609 (11.3)	9423 (10.1)		
Demographics &		Asian	1283 (13.1)	238 (3.3)	1437 (10.1)	6911 (7.4)	-	
socioeconomics		Caucasian/White	3538 (36.2)	6167 (86.5)	7002 (49.1)	52667 (56.5)		
of mothers		Hispanic/Latino	2422 (24.7)	226 (3.2)	2180 (15.3)	15543 (16.7)	< 0.001	Chi- squared
		Native American	34 (0.3)	10 (0.1)	39 (0.3)	201 (0.2)]	1
		Other	820 (8.4)	225 (3.2)	1207 (8.5)	5747 (6.2)		
		Unknown	214 (2.2)	122 (1.7)	790 (5.5)	2662 (2.9)		
		Mother on Medicaid, n (%)	2821 (28.8)	229 (3.2)	3258 (22.8)	29219 (31.4)	< 0.001	Chi- squared
Health Insurance		Child on Medicaid, n (%)	2461 (25.1)	105 (1.5)	2381 (16.7)	27392 (29.4)	< 0.001	Chi- squared
		Child switched to Medicaid, n (%)	25 (0.3)	7 (0.1)	28 (0.2)	154 (0.2)	0.07	Chi- squared
		Year of birth, median [Q1,Q3]	2015 [2013,2016]	2015 [2013,2017]	2018 [2017,2019]	2015 [2011,2017]	< 0.001	Kruskal- Wallis
		Pre-term birth, n (%)	1299 (13.3)	844 (11.8)	1671 (11.7)	11676 (12.5)	.0.001	Chi-
Pirth of shildron	B	irth facility, n (%)					<0.001	squared
Birti of children		Mount Sinai Hospital	8370 (85.5)	6518 (91.4)	9011 (63.2)	79350 (85.2)		
		Mount Sinai West	858 (8.8)	262 (3.7)	1934 (13.6)	5916 (6.4)	< 0.001	Chi- squared
		Other	558 (5.7)	350 (4.9)	3319 (23.3)	7888 (8.5)		
Record		latest follow-up age (days), median [O1 O3]	17.0 [0.0.713.0]	0.0	4.0 [0.0.401.0]	16.0 [0.0.596.0]	< 0.001	Kruskal- Wallis
completeness		# of encounters, median [Q1,Q3]	2.00 [1.00,16.00]	1.00 [1.00,2.00]	2.00 [1.00,12.00]	2.00 [1.00,6.00]	< 0.001	Kruskal- Wallis

Table 2: Demographic information of cohorts by carrier screening status.

Note than p-value indicates difference between all carrier screening groups.

PhenoIndex Criteria	n (%)
multiple ER visits	3919 (4.2)
developmental delay	3159 (3.4)
multiple specialists	3091 (3.3)
respiratory support	2838 (3.0)
imaging	1113 (1.2)
genetic tests	704 (0.8)
prolonged in-patient stays	500 (0.5)
metabolic tests	448 (0.5)
death	371 (0.4)
heart surgeries	304 (0.3)
prolonged NICU stay	279 (0.3)
feeding support	132 (0.1)
metabolic ICD codes	82 (0.1)

Table 3: Number of children passing each individual *PheIndex* criteria.

Table 4: Accuracy of digital phenotype algorithm compared to chart review for individual *PheIndex* criteria.

PhenoIndex Criteria	Accuracy
prolonged NICU stay	81%
prolonged in-patient stays	98%
multiple ER visits	94%
multiple specialists	93%
feeding support	96%
respiratory support	90%
imaging	97%
genetic tests	96%
metabolic tests	96%
death	98%
metabolic ICD codes	97%
developmental delay	93%
heart surgeries	97%

		Clinical geneticist classification					
ex		Does not have genetic	Definitively or	Unknown	Total		
ndo		disease	possibly has	(insufficient			
lou			genetic disease	information)			
ass	Negative	91 (True Negative)	9 (False Negative)	0	100		
Ci Pi	Positive	3 (False positive)	85 (True Positive)	12	100		
	Total	94	94	12	200		

Table 5: Performance of *PheIndex* Classification against chart review.

	CS-S	CS-M	CS-L	All	P-Value	Test
#	9786	7130	14264	93154		
multiple ER visits, n (%)	623 (6.4)	25 (0.4)	424 (3.0)	3919 (4.2)	< 0.001	Chi-squared
developmental delay, n (%)	515 (5.3)	138 (1.9)	522 (3.7)	3159 (3.4)	< 0.001	Chi-squared
multiple specialists, n (%)	497 (5.1)	121 (1.7)	431 (3.0)	3091 (3.3)	< 0.001	Chi-squared
respiratory support, n (%)	348 (3.6)	201 (2.8)	665 (4.7)	2838 (3.0)	< 0.001	Chi-squared
imaging, n (%)	132 (1.3)	43 (0.6)	162 (1.1)	1113 (1.2)	< 0.001	Chi-squared
genetic tests, n (%)	75 (0.8)	31 (0.4)	95 (0.7)	704 (0.8)	0.03	Chi-squared
prolonged in-patient stays, n (%)	51 (0.5)	15 (0.2)	45 (0.3)	500 (0.5)	0.002	Chi-squared
metabolic tests, n (%)	49 (0.5)	26 (0.4)	69 (0.5)	448 (0.5)	0.38	Chi-squared
death, n (%)	44 (0.4)	10 (0.1)	41 (0.3)	371 (0.4)	0.001	Chi-squared
heart surgeries, n (%)	23 (0.2)	7 (0.1)	17 (0.1)	304 (0.3)	0.03	Chi-squared
prolonged NICU stay, n (%)	24 (0.2)	9 (0.1)	27 (0.2)	279 (0.3)	0.22	Chi-squared
feeding support, n (%)	13 (0.1)	3 (0.0)	13 (0.1)	132 (0.1)	0.16	Chi-squared
metabolic ICD codes, n (%)	3 (0.0)	4 (0.1)	11 (0.1)	82 (0.1)	0.38	Chi-squared
# of PheIndex criteria, mean (SD)	0.24 (0.69)	0.09 (0.41)	0.18 (0.59)	0.18 (0.63)	< 0.001	One-way ANOVA
PheIndex Score, mean (SD)	0.31 (0.98)	0.13 (0.62)	0.24 (0.87)	0.25 (0.97)	< 0.001	One-way ANOVA

Table 6: Number of children passing each individual *PheIndex* criteria split by carrier screen testing status.